Table 3.
Blood glucose level, weight progression, and positron emission tomography studies of glucose utilization (standardized unit values) in control and tryptamine-treated mice.12
| Values | Control animals (n = 6) | Tryptamine treated (n = 6) |
|---|---|---|
| Blood glucose (mg/dL) | 138 ± 19 | 129 ± 19 |
| Weight progression (%) | 11.4 ± 4.5 | 20.8 ± 3.8 |
| Glucose utilization | ||
| Whole brain | 0.94 ± 0.11 | 0.95 ± 0.18 |
| Cerebellum | 0.72 ± 0.12 | 0.68 ± 0.07 |
| Cingulate | 1.29 ± 0.10 | 1.27 ± 0.13 |
| Hippocampus | 1.24 ± 0.11 | 1.17 ± 0.17 |
| Olfactory area | 1.43 ± 0.21 | 1.36 ± 0.13 |
| Striatum | 1.21 ± 0.12 | 1.17 ± 0.16 |
Table modified from Paley et al.12 Tryptamine-treated mice: after tryptamine administration of 200-400 µg per mouse through intraperitoneal injections during 63 days12.